About Conexio Genomics
Conexio Genomics is a Healthcare company based in Fremantle (Australia) founded in 2003, and was acquired by Illumina in January 2016. Products for genetic sequencing and mutation detection are developed. The company was acqui-hired. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Conexio Genomics develops products for genetic sequencing and mutation detection. Its flagship product TruSight HLA sequencing solution provides phase-resolved HLA typing in a single assay and was co-developed with Illumina. In addition, the company also provides variant analysis software Assign that can be used in conjunction with its TruSight panel, or independently with other gene panels.
- Headquarters Fremantle, Australia
- Stage Acquired
- SectorsHealthcare
- Website conexio-genomics.com
- Social LinkedIn
- Acquired by Illumina (Jan 2016)
Investors in Conexio Genomics
Conexio Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Illumina.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Conexio Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Conexio Genomics
2 dated milestones of Conexio Genomics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Conexio Genomics is founded.
- Exit Acquired by Illumina.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Conexio Genomics
Conexio Genomics was founded in 2003.
Conexio Genomics is headquartered in Fremantle, Australia. It is registered at Fremantle, Western Australia, Australia.
Conexio Genomics develops products for genetic sequencing and mutation detection. Its flagship product TruSight HLA sequencing solution provides phase-resolved HLA typing in a single assay and was co-developed with Illumina. In addition, the company also provides variant analysis software Assign that can be used in conjunction with its TruSight panel, or independently with other gene panels.
Conexio Genomics has 1 investor. Key investors include Illumina.
Yes. Conexio Genomics was acquired by Illumina in January 2016.